Solara Active Pharma Sciences delivered a remarkable financial turnaround in the March 2026 quarter, reporting a consolidated net profit of ₹9.60 crore compared to a net loss of ₹2.10 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this represents a complete reversal of fortunes for the pharmaceutical company. The market responded positively to the results, with stock price surging 15.20% to ₹584.85 following the announcement of the quarterly performance. The company's sales surged 41.86% to ₹387.29 crore in Q4 FY26, significantly outpacing the ₹273.01 crore recorded in Q4 FY25, demonstrating strong operational momentum.
The stock experienced a modest 1.36% weekly gain, slightly outperforming the Sensex's 1.25% rise during the week. On May 5, 2026, MarketsMOJO upgraded the company's rating from Strong Sell to Sell, driven by improving technical indicators despite ongoing fundamental challenges. The upgrade reflects a cautious optimism as weekly MACD and On-Balance Volume (OBV) turned mildly bullish, suggesting potential base formation. However, fundamental concerns remain, including a negative five-year CAGR of -19.87% in operating profits, low return on equity at 2.54%, and a high Debt to EBITDA ratio of 3.32 times. The stock's recent quarterly results were flat, with a loss before tax of ₹-10.68 crores and EPS of ₹-3.92, underscoring ongoing operational challenges.
The company's diversified business portfolio showed mixed performance across segments during the quarter. As reported by Business Standard, revenue from base business jumped 36% YoY to ₹307 crore while revenue from Ibuprofen business climbed 61% YoY to ₹849 crore. However, the Ibuprofen business continues to face profitability challenges, operating at a negative 21% EBITDA margin with gross margins of approximately 23%. In contrast, the base business demonstrates superior profitability, operating at a ~26% EBITDA margin with gross margins of ~54%, reinforcing the company's strategic pivot toward sustainable, profitable growth.
Despite the strong quarterly performance, the company faced challenges throughout the full financial year. As reported by Business Standard, net loss for the full year ended March 2026 stood at ₹7.41 crore, a significant decline from the net profit of ₹0.54 crore achieved in the previous year. However, the company showed resilience with annual sales growing 6.64% to ₹1,368.98 crore in FY26, compared to ₹1,283.76 crore in FY25, indicating steady business expansion despite annual profitability challenges.
